AI assistant
IONIS PHARMACEUTICALS INC — Director's Dealing 2014
Jan 24, 2014
30591_dirs_2014-01-24_f7fce4c6-101b-4bc5-bea2-7907226460e5.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: ISIS PHARMACEUTICALS INC (ISIS)
CIK: 0000874015
Period of Report: 2014-01-24
Reporting Person: KLEIN JOSEPH III (Director)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2014-01-24 | Common Stock | M | 7500 | $16.32 | Acquired | 9813 | Direct |
| 2014-01-24 | Common Stock | S | 7500 | $48.6797 | Disposed | 2313 | Direct |
| 2014-01-24 | Common Stock | M | 2813 | $12.94 | Acquired | 5126 | Direct |
| 2014-01-24 | Common Stock | S | 2813 | $48.6102 | Disposed | 2313 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2014-01-24 | Director Stock Option (right to buy) | $16.32 | M | 7500 | Disposed | 2019-06-30 | Common Stock (7500) | Direct |
| 2014-01-24 | Director Stock Option (right to buy) | $12.94 | M | 2813 | Disposed | 2022-07-01 | Common Stock (2813) | Direct |
Footnotes
F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $48.75 to $48.62, inclusive. The reporting person undertakes to provide to Isis Pharmaceuticals, Inc., any security holder of Isis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (1) on this Form 4.
F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $48.60 to $48.62, inclusive. The reporting person undertakes to provide to Isis Pharmaceuticals, Inc., any security holder of Isis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (1) on this Form 4.
F3: Grant of 7/2/12 to reporting person of stock options under the Isis Pharmaceuticals, Inc. 2002 Non-Employee Directors' Stock Option Plan. The option vests and becomes exercisable in four equal annual installments, the first installment vestong on 7/2/13. The option shall be fully vested and exercisable on 7/2/16. Following the reported option exercise, the option was exercisable as to 0 shares on 1/24/14.